Ngā hua rapu - Nicola Richardson‐Harman
- E whakaatu ana i te 1 - 7 hua o te 7
-
1
A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge mā George W. Buchman, Matthew E. Cohen, Yuhong Xiao, Nicola Richardson‐Harman, Peter Silvera, Louis J. DeTolla, Heather L. Davis, Roselyn J. Eisenberg, Gary H. Cohen, Stuart N. Isaacs
I whakaputaina 2010Artigo -
2
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film mā Katherine Bunge, Charlene S. Dezzutti, Lisa C. Rohan, Craig W. Hendrix, Mark A. Marzinke, Nicola Richardson‐Harman, Bernard J. Moncla, Bríd Devlin, Leslie A. Meyn, Hans Spiegel, Sharon L. Hillier
I whakaputaina 2015Artigo -
3
Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings mā Beatrice A. Chen, Lori Panther, Mark A. Marzinke, Craig W. Hendrix, Craig Hoesley, Ariane van der Straten, Marla Husnik, Lydia Soto‐Torres, Annaléne Nel, Sherri Johnson, Nicola Richardson‐Harman, Lorna K. Rabe, Charlene S. Dezzutti
I whakaputaina 2015Artigo -
4
RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate mā Peter A. Anton, Ross Cranston, Angela D. M. Kashuba, Craig W. Hendrix, Namandjé N. Bumpus, Nicola Richardson‐Harman, Julie Elliott, Laura Janocko, Elena Khanukhova, Robert J. Dennis, William G. Cumberland, Chuan Ju, Alex Carballo‐Diéguez, Christine Mauck, Ian McGowan
I whakaputaina 2012Artigo -
5
A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study) mā Ian McGowan, Ross Cranston, Kathryn Duffill, Aaron Siegel, Jarret Engstrom, A. T. Nikiforov, Cindy Jacobson, Khaja K. Rehman, Julie Elliott, Elena Khanukhova, Kaleab Z. Abebe, Christine Mauck, Hans Spiegel, Charlene S. Dezzutti, Lisa C. Rohan, Mark A. Marzinke, Hiwot Hiruy, Craig W. Hendrix, Nicola Richardson‐Harman, Peter A. Anton
I whakaputaina 2015Artigo -
6
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic a... mā Ian McGowan, Charlene S. Dezzutti, Aaron Siegel, Jarret Engstrom, Alexiy Nikiforov, Kathryn Duffill, Cory Shetler, Nicola Richardson‐Harman, Kaleab Z. Abebe, David Back, Laura Else, Deidre Egan, Saye Khoo, James E. Egan, Ronald Stall, Peter Williams, Khaleel K Rehman, Amy Adler, Rhonda M. Brand, Beatrice Chen, Sharon L. Achilles, Ross Cranston
I whakaputaina 2016Artigo -
7
Biological and Technical Variables Affecting Immunoassay Recovery of Cytokines from Human Serum and Simulated Vaginal Fluid: A Multicenter Study mā Raina N. Fichorova, Nicola Richardson‐Harman, Massimo Alfano, Laurent Bélec, Cédric Carbonneil, Silvia Chen, Lisa A. Cosentino, Kelly A. Curtis, Charlene S. Dezzutti, Betty A. Donoval, Gustavo F. Doncel, Melissa Donaghay, Jean‐Charles Grivel, Esmeralda Guzman, Madeleine Hayes, Betsy C. Herold, Sharon L. Hillier, Carol Lackman-Smith, Alan Landay, Leonid Margolis, Kenneth H. Mayer, Jenna-Malia Pasicznyk, Melanie Pallansch-Cokonis, Guido Poli, Patricia Reichelderfer, Paula Roberts, Irma Rodriguez, Héla Saïdi, Rosaria Rita Sassi, Robin J. Shattock, James E. Cummins
I whakaputaina 2008Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Pharmacology
Pharmacodynamics
Pharmacokinetics
Human immunodeficiency virus (HIV)
Adverse effect
Alternative medicine
Biology
Environmental health
Health services
Internal medicine
Microbicide
Microbicides for sexually transmitted diseases
Pathology
Placebo
Population
Vaginal microbicide
Virology
Biotechnology
Chemistry
Ex vivo
Immunology
In vivo
Maraviroc
Anesthesia
Antibody
Antiretroviral therapy
Attenuated vaccine
Biochemistry
Chemiluminescence